Aarti Drugs rose 5.01% to Rs 768.70 at 9:26 IST on BSE after the company fixed 19 January 2018 as record date for buyback of upto 2.75 lakh shares representing upto 1.15% stake at Rs 875 per share.
The announcement was made after market hours yesterday, 8 January 2018.Meanwhile, the S&P BSE Sensex was up 38.73 points, or 0.11% to 34,391.52.
On the BSE, 25,000 shares were traded in the counter so far, compared with average daily volumes of 12,000 shares in the past two weeks. The stock had hit a high of Rs 784.80 so far during the day, which is also its 52-week high for the counter. The stock had hit a low of Rs 760.05 so far during the day. The stock hit a 52-week low of Rs 456.25 on 24 May 2017.
On a consolidated basis, Aarti Drugs' net profit rose 6.9% to Rs 23.60 crore on 1.3% growth in net sales to Rs 319.27 crore in Q2 September 2017 over Q2 September 2016.
Aarti Drugs is a pharmaceutical company. The company has a strong presence in the anti-diarrhea, anti-inflammatory therapeutic groups. With its manufacturing facilities at Tarapur and Sarigam, the company manufactures vitamins, anti-arthritis, anti-fungal, antibiotics, ACE inhibitors, besides its range in anti-diabetic, anti-cholinergic, sedatives and anti-depressant drugs.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
